Previously, in preclinical and clinical studies, we reported that XBP1/CD138/CS1 multipeptide can induce antigen-specific memory CTL against MM [14–18], and that this therapeutic approach when combined with optimal immune modulators may further overcome immunosuppression characteristic of MM [19, 20]. Here, XBP1 is linked to Miyoshi myopathy.